

Thirupathi Dongala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557660/publications.pdf>

Version: 2024-02-01

34
papers

515
citations

566801

15
h-index

713013

21
g-index

36
all docs

36
docs citations

36
times ranked

144
citing authors

#	ARTICLE	IF	CITATIONS
1	Reverse-phase LC method development and validation for the quantification of acetazolamide and its specified and unspecified degradation products in hard gelatin capsule formulations. Journal of the Iranian Chemical Society, 2022, 19, 775-784.	1.2	1
2	Eco-friendly and green chromatographic method for the simultaneous determination of chlorocresol and betamethasone dipropionate in topical formulations using Boxâ€œBehnken design. Journal of the Iranian Chemical Society, 2022, 19, 1397-1412.	1.2	34
3	A validated stabilityâ€œindicating reversedâ€œphaseâ€œHPLC method for dipyrindamole in the presence of degradation products and its processâ€œrelated impurities in pharmaceutical dosage forms. Biomedical Chromatography, 2022, 36, e5247.	0.8	6
4	Stabilityâ€œindicating reversedâ€œphaseâ€œHPLC method development and validation for sacubitril/valsartan complex in the presence of impurities and degradation products: Robustness by qualityâ€œbyâ€œdesign approach. Biomedical Chromatography, 2022, 36, e5240.	0.8	16
5	A simple isocratic LC method for quantification of traceâ€œlevel inorganic degradation impurities (ferricyanide, ferrocyanide, nitrite, and nitrate) in sodium nitroprusside injection and robustness by quality using design approach. Biomedical Chromatography, 2022, 36, e5269.	0.8	13
6	Development and validation of liquid chromatography method for determination of lbrutinib in finished dosage forms using quality by design approach. Separation Science Plus, 2022, 5, 254-266.	0.3	16
7	Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Erythromycin Related Impurities in Topical Dosage Form. Pharmaceutical Chemistry Journal, 2022, 56, 131-137.	0.3	15
8	Quantitative estimation of Fulvestrant injection 505(j) composition and impurities profile by capillary gas chromatography and HPLC-PDA techniques. Journal of the Iranian Chemical Society, 2021, 18, 1443-1454.	1.2	2
9	Development and validation of a RP-UPLC method for the determination of betamethasone dipropionate impurities in topical formulations using a multivariate central composite design. Analytical Methods, 2021, 13, 3705-3723.	1.3	31
10	Lowâ€œlevel determination of 4â€œchlorobutylâ€œ(S) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td ()â€œ{4â€œchloroâ€œ2â€œ(4â€œcyclopropylâ€œsubstance by LCâ€œMS. Biomedical Chromatography, 2021, 35, e5086.	0.8	2
11	Quality by design with design of experiments approach for development of a stabilityâ€œindicating LC method for enzalutamide and its impurities in soft gel dosage formulation. Biomedical Chromatography, 2021, 35, e5062.	0.8	21
12	A simple and rapid HPLC method for determination of parabens and their degradation products in pharmaceutical dosage forms. Biomedical Chromatography, 2021, 35, e5152.	0.8	19
13	A Development and Validation of RP-HPLC Method for the Determination of Degradation Impurities in Anagrelide Dosage Form. Analytical Chemistry Letters, 2021, 11, 708-718.	0.4	2
14	Stabilityâ€œindicating RPâ€œHPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach. Biomedical Chromatography, 2020, 34, e4719.	0.8	31
15	Stability-indicating LC method for the simultaneous determination of methyl paraben, propyl paraben, butylated hydroxytoluene and alpha-tocopherol contents in marijuana capsules. Journal of the Iranian Chemical Society, 2020, 17, 631-638.	1.2	6
16	QbDâ€œbased development of an extraction procedure for simultaneous quantification of telmisartan, amlodipine besylate and chlorthalidone in combination complex matrix formulation. Biomedical Chromatography, 2020, 34, e4755.	0.8	10
17	Novel stability indicating UHPLC method development and validation for simultaneous quantification of hydrocortisone acetate, pramoxine hydrochloride, potassium sorbate and sorbic acid in topical cream formulation. Talanta Open, 2020, 1, 100004.	1.7	23
18	SELECTIVE TRACE LEVEL DETERMINATION OF 1,4-DIOXANE CONTENT IN SODIUM LAURETH SULFATE RAW MATERIAL BY GAS CHROMATOGRAPHIC-FLAME IONIZATION DETECTION METHOD. Asian Journal of Pharmaceutical and Clinical Research, 2020, , 116-120.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach. <i>Chromatographia</i> , 2020, 83, 1269-1281.	0.7	21
20	A simple high-performance liquid chromatography method development for Carbidopa and Levodopa impurities: Evaluation of risk assessment before method validation by Quality by Design approach. <i>Separation Science Plus</i> , 2020, 3, 530-539.	0.3	23
21	Quality by design with design of experiments approach for the development of a stability-indicating LC method for benzonatate and its impurities in liquid oral dosage form. <i>Separation Science Plus</i> , 2020, 3, 276-285.	0.3	14
22	QbD based development of HPLC method for simultaneous quantification of Telmisartan and Hydrochlorothiazide impurities in tablets dosage form. <i>Practical Laboratory Medicine</i> , 2020, 21, e00169.	0.6	28
23	A novel RP-HPLC refractive index detector method development and validation for determination of trace-level alcohols (un-sulfated) in sodium lauryl sulfate raw material. <i>Biomedical Chromatography</i> , 2020, 34, e4827.	0.8	11
24	Estimation of ramipril and telmisartan in human plasma by LC-MS/MS: Application in pharmacokinetic study. <i>Separation Science Plus</i> , 2020, 3, 191-199.	0.3	2
25	In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 613393.	1.6	18
26	Development and validation of a generic RP-HPLC PDA method for the simultaneous separation and quantification of active ingredients in cold and cough medicines. <i>Biomedical Chromatography</i> , 2019, 33, e4641.	0.8	24
27	HPLC-UV Method Development for the Determination of EDTA in Oxycodone HCl Oral Liquids with Derivatization Technique. Robustness by Design of Experiments Approach. <i>Analytical Chemistry Letters</i> , 2019, 9, 594-607.	0.4	9
28	Stability-indicating HPLC method for simultaneous quantification of 14 impurities in exceedrin tablet formulations and identification of new impurity by LC-MS in accelerated stability studies. <i>Biomedical Chromatography</i> , 2019, 33, e4608.	0.8	25
29	A novel UPLC-PDA isocratic method for the quantification fulvestrant in oil-based pre-filled syringe injection matrix formulations. <i>Journal of Analytical Science and Technology</i> , 2019, 10, .	1.0	21
30	RP-HPLC Stability Indicating Method Development and Validation of Pseudoephedrine Sulfate and Related Organic Impurities in Tablet Dosage Forms, Robustness by QbD Approach. <i>Analytical Chemistry Letters</i> , 2019, 9, 697-710.	0.4	17
31	Development and Validation of RP-HPLC Method for Simultaneous Determination of Diclofenac Potassium and its Process Related Impurities in Solid Oral Dosage Form. <i>Journal of Chromatography & Separation Techniques</i> , 2018, 09, .	0.2	5
32	Simultaneous Determination of Related Organic Impurities of Ibuprofen and Paracetamol in Combination Solid Dosage Form by Rp-hplc With Qbd Approach. <i>Oriental Journal of Chemistry</i> , 2017, 33, 1461-1468.	0.1	24
33	Development and Validation of a Stability-Indicating LC Method for the Simultaneous Estimation of Levodropropizine, Chloropheniramine, Methylparaben, Propylparaben, and Levodropropizine Impurities. <i>Scientia Pharmaceutica</i> , 2013, 81, 139-150.	0.7	15
34	TRACE LEVEL DETERMINATION OF SODIUM CHLORIDE AND SODIUM SULFATE CONTENT IN SODIUM LAURETH SULFATE RAW MATERIAL USING COUNTER CATION-EXCHANGE HPLC WITH INDIRECT ULTRAVIOLET DETECTION. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 119-123.	0.3	0